VIKAS KUNDRA to Treatment Outcome
This is a "connection" page, showing publications VIKAS KUNDRA has written about Treatment Outcome.
Connection Strength
0.090
-
In Vivo Assessment of Ovarian Tumor Response to Tyrosine Kinase Inhibitor Pazopanib by Using Hyperpolarized 13C-Pyruvate MR Spectroscopy and 18F-FDG PET/CT Imaging in a Mouse Model. Radiology. 2017 12; 285(3):830-838.
Score: 0.034
-
Staging, surveillance, and evaluation of response to therapy in renal cell carcinoma: role of MDCT. Abdom Imaging. 2014 Feb; 39(1):66-85.
Score: 0.027
-
Bempegaldesleukin (BEMPEG; NKTR-214) efficacy as a single agent and in combination with checkpoint-inhibitor therapy in mouse models of osteosarcoma. Int J Cancer. 2021 04 15; 148(8):1928-1937.
Score: 0.011
-
Tumour angiogenesis regulation by the miR-200 family. Nat Commun. 2013; 4:2427.
Score: 0.006
-
Dual inhibition of tumor energy pathway by 2-deoxyglucose and metformin is effective against a broad spectrum of preclinical cancer models. Mol Cancer Ther. 2011 Dec; 10(12):2350-62.
Score: 0.006
-
Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer. Lancet Oncol. 2011 Nov; 12(12):1109-17.
Score: 0.006